Good afternoon :)
Place Order
Add to Watchlist

Wockhardt Ltd

WOCKPHARMA

Wockhardt Ltd

WOCKPHARMA
Health CarePharmaceuticals
SmallcapWith a market cap of ₹23,368 cr, stock is ranked 325
High RiskStock is 4.05x as volatile as Nifty
1,433.600.33% (-4.70)
1,433.600.33% (-4.70)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹23,368 cr, stock is ranked 325
High RiskStock is 4.05x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹23,368 cr, stock is ranked 325
High RiskStock is 4.05x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-81.146.38
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.906.610.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Wockhardt Limited manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -4.79%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 1.68% to 0.76%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue4,519.324,128.864,057.133,681.992,977.363,825.003,250.002,773.002,881.003,050.00
Raw Materialssubtract1,678.091,687.941,619.001,605.851,129.421,262.001,180.001,027.001,179.002,814.00
Power & Fuel Costsubtract113.99110.1077.8093.3085.4182.0098.00103.00107.00
Employee Costsubtract950.77966.51937.06800.38743.33763.00749.00637.00629.00
Selling & Administrative Expensessubtract660.85709.73684.13554.77327.73383.00404.00326.00313.00
Operating & Other expensessubtract555.28527.53975.27550.02439.07423.00684.00751.00545.00
Depreciation/Amortizationsubtract141.91148.93149.53163.95224.14246.00247.00251.00223.00222.00
Interest & Other Itemssubtract128.96225.27255.49265.14275.74249.00299.00302.00305.00296.00
Taxes & Other Itemssubtract38.75-51.43-32.85-156.89-178.26-269.00-167.00-65.0043.006.00
EPS20.95-16.32-50.69-16.20-5.7657.08-18.47-38.80-31.13-18.77
DPS0.009.220.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Mar 8PDF
FY 2023

Annual report

PDF

Investor Presentation

Feb 21PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Wockhardt Ltd-50.476.38
Sun Pharmaceutical Industries Ltd45.106.440.75%
Cipla Ltd29.414.520.87%
Torrent Pharmaceuticals Ltd68.5016.550.84%

Price Comparison

Compare WOCKPHARMA with any stock or ETF
Compare WOCKPHARMA with any stock or ETF
WOCKPHARMA
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 2.90%

High Pledged Promoter Holding

Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding49.09%7.09%2.79%6.62%34.41%

Mar 2024

Jun 2024

Sep 2024

Nov 2024

Shareholding History

SepDec '23MarJunSepNov3.02%4.17%5.49%5.93%6.70%6.62%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 4.14%

Top 5 Mutual Funds holding Wockhardt Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
ICICI Prudential Equity & Debt Fund - Direct Plan - Growth

Growth
0.3843%0.22%0.05%121/203 (+3)
Samco Active Momentum Fund - Direct Plan - Growth Option

Growth
0.3428%9.42%2.51%4/81 (+1)
ICICI Prudential ELSS Tax Saver Fund - Growth - Direct Plan

Growth
0.3235%0.53%0.13%57/88 (+3)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

WOCKPHARMA has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateNov 17, 2016

Interim
Interim | Div/Share: ₹10.00

Dividend/Share

10.00

Ex DateEx Date

Nov 17, 2016

Cash Dividend

Ex DateEx DateNov 13, 2014

Interim
Interim | Div/Share: ₹20.00

Dividend/Share

20.00

Ex DateEx Date

Nov 13, 2014

Cash Dividend

Ex DateEx DateFeb 17, 2014

Interim 2
Interim 2 | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Feb 17, 2014

Cash Dividend

Ex DateEx DateNov 7, 2013

Interim
Interim | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Nov 7, 2013

Cash Dividend

Ex DateEx DateAug 22, 2013

Final
Final | Div/Share: ₹5.00

Dividend/Share

5.00

Ex DateEx Date

Aug 22, 2013

News & Opinions
Earnings
Wockhardt reports consolidated net loss of Rs 22.00 crore in the September 2024 quarter

Net Loss of Wockhardt reported to Rs 22.00 crore in the quarter ended September 2024 as against net loss of Rs 77.00 crore during the previous quarter ended September 2023. Sales rose 7.44% to Rs 809.00 crore in the quarter ended September 2024 as against Rs 753.00 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales809.00753.00 7 OPM %13.609.56 - PBDT46.0020.00 130 PBT-9.00-35.00 74 NP-22.00-77.00 71 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Wockhardt to conduct board meeting

Wockhardt will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Spotlight
Wockhardt slumps on launching QIP at discount

The floor price indicates a steep discount of 8.5% over the stock's closing price on Wednesday. The media reported that the QIP is aimed to raise up to Rs 1,000 crore, with an additional greenshoe option of Rs 200 crore. A QIP is a method by which a company raises funds by allotting shares to eligible institutional buyers. According to reports, the QIP is expected to dilute Wockhardt's equity by around 5.57% of its post-issue capital. Based on the September shareholding pattern, promoters of Wockhardt held a 51.99% stake in the company. Mumbai-based Wockhardt is a research based global pharmaceutical and biotech company. Employing around ~2600 people and 27 nationalities, it has a presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India & UK and a manufacturing facility in Ireland. Around 78% of its global revenues is coming from international businesses. Powered by Capital Market - Live

4 weeks agoCapital Market - Live
Corporate
Wockhardt files its Aspart insulin injection with DCGI

Wockhardt announced the filing of its fast-acting insulin analog, Aspart injection (ASPARAPID), with the Drugs Controller General of India (DCGI). This significant milestone reflects Wockhardt's ongoing commitment to address the growing diabetes epidemic both in India and globally. Wockhardt's Aspart insulin injection (ASPARAPID) is an indigenously developed product, underscoring the company's end-to-end capabilities in research development - from research to production through in-house development. It offers enhanced quality and accessibility for patients. ASPARAPID will be available in cartridges, vials, and prefilled disposable pens, offering flexibility to the patients for management of diabetes. The market size of Aspart in India is currently estimated over Rs 260 crore with only 2 players and is expected to grow significantly in the coming years. 'We are proud of adding another feather in our diabetes biosimilars portfolio through filing of insulin Aspart injection in a market that has limited competition. This reinforces Wockhardt's ability to develop and manufacture complex biosimilars domestically,' said Dr. Habil Khorakiwala, Founder Chairman of Wockhardt. 'Our aim is to make world-class diabetes care accessible to patients in India and globally and to contribute meaningfully to the management of diabetes.' Wockhardt is also developing additional insulin analogs and GLP-1 agonists as part of its comprehensive strategy to provide advanced diabetes care solutions. The introduction of these products will further strengthen Wockhardt's diabetes portfolio, offering patients more effective treatment options for managing their condition. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Wockhardt's once-a-day antibiotic drug 'WCK 6777' successfully concludes Phase I study

Wockhardt is advancing the development of several new antibiotics aimed at combating difficult-to-treat drug-resistant bacterial infections that drive anti-microbial resistance (AMR) linked mortality and morbidity. Recently, one of its unique once-a-day, '-lactam enhancer based MDR-active antibiotic, WCK 6777 (Ertapenem/Zidebactam) has successfully completed a Phase I study conducted by the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in US. Recognizing the therapeutic potential of WCK 6777 for infections caused by MDR Gram negative pathogens, DMID of NIH had selected this drug for Phase I studies. Zidebactam has already demonstrated promising safety profile in Phase I and on-going Phase II & III studies in combination with Cefepime (WCK 5222). Additionally, recognizing its potential to meet significant unmet medical needs, the US FDA has recently granted Fast Track designation to WCK 6777 for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and complicated intra-abdominal infections (cIAI). WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy (OPAT) in ambulatory settings. WCK 6777 is active against entire range of meropenem-resistant Gram negative pathogens generally encountered in community as well as hospital urinary tract infections (UTI) and intra-abdominal infections (IAI). Such a therapeutic option is expected to cut hospital admissions, facilitate early patient discharge and thus offer patient-centred care for MDR infections. Phase I study of WCK 6777 involved 52 participants and was designed as a double-blind, placebo-controlled, multiple-ascending dose trial in healthy volunteers. The trial rigorously assessed the safety and pharmacokinetics of WCK 6777, administering intravenous doses higher than the anticipated clinical dose over a period of 7 days. Results demonstrated a promising safety profile, with WCK 6777 (up to 3 grams + 3 grams daily) being well-tolerated, and no serious or unexpected adverse events reported. None of the subjects withdrew or were discontinued from the study due to treatment-related adverse events. Pharmacokinetic analysis revealed consistent exposure levels of both ertapenem and zidebactam, with no significant interactions when co-administered daily for the duration of the study. The promising safety data from this study paves the way for the advancement of WCK 6777 into Phase II / III clinical trials. Globally, incidence of UTI were 404.61 million with 236,790 deaths estimated in 2019. It is estimated that 1 in 100 of US adults will experience a cUTI each year, resulting in approximately 2.8 million cUTI cases and annualized total US costs in excess of $ 6 billion. There are 600,000 hospital admissions among adults for cUTIs each year in the United States with each episode costing an average of $ 9,441. Emerging therapeutic role of WCK 6777 makes it uniquely positioned to cater to the vast unmet need in the management of infections outside the hospital.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Wockhardt announces cessation of director

Wockhardt announced that Tasneem Vikram Singh Mehta (DIN: 05009664) ceased to be Independent Director of the Company upon completion of her second term of 5 (Five) consecutive years on 29 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Wockhardt's investigational drug, Zaynich' demonstrates its ability to manage complex infections

In the past year, Wockhardt's investigational drug, Zaynich' (Zidebactam/Cefepime), has successfully treated over 35 critically ill patients in India and US who were suffering from extremely drug-resistant infections under compassionate use. This drug has once again demonstrated its effectiveness in managing complex, deep-seated infections. A recent notable case involved a 64-year-old patient with Type 2 diabetes and hypertension, who had been battling pulmonary and meningeal tuberculosis for about a year. Following a spinal puncture to withdraw cerebrospinal fluid (CSF), the patient developed fever, drowsiness, and unconsciousness, leading to mechanical ventilation and a diagnosis of bacterial meningitis. The condition was confirmed when CSF analysis identified a pan-drug resistant super-bug, Pseudomonas. Initial treatments with Ceftazidime/Avibactam, Aztreonam, and Meropenem failed to halt the patient's deterioration, marked by persistent fever spikes and increasing infection markers such as C-Reactive Protein (CRP), procalcitonin, and white blood cells (WBC). Due to the significant toxicity and limited ability of Colistin and Polymyxin in crossing the blood-brain barrier, these options were deemed unsuitable. Faced with no alternatives, a multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use. Treatment was administered for three weeks. Remarkably, within a short period, the patient's clinical condition improved, with CRP and procalcitonin levels decreasing, and the patient was successfully taken off the ventilator. CSF tests showed the eradication of the pathogen just one week into treatment, and subsequent tests confirmed the absence of Pseudomonas after three weeks of Zidebactam/Cefepime. The patient became clinically stable and all symptoms resolved leading to discharge from the hospital. The drug was well-tolerated throughout the treatment period. Meningitis, an inflammation of the tissues surrounding the brain and spinal cord, poses significant treatment challenges due to the difficulty of antibiotics in penetrating the blood-brain barrier. This case highlights Zidebactam/Cefepime's remarkable ability to tackle infections in difficult-to-treat body sites. This represents the first case of nosocomial meningitis caused by multidrug-resistant Pseudomonas successfully treated with Zidebactam/Cefepime, underscoring its potential as a valuable therapeutic option. Zaynich, combination of Cefepime and Zidebactam, is Wockhardt's novel patented antibiotic, targeted towards multi-drug resistant Gram-negative infections. It is currently undergoing a multi-national Phase III study which would support its registration/marketing authorization globally. Earlier, multiple Phase I studies including clinical pharmacology studies with Zidebactam/Cefepime were conducted in US. Zaynich (Zidebactam/Cefepime) is also undergoing a Phase II study in India for the treatment of carbapenem-resistant infections.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Wockhardt allots 8,610 equity shares under ESOS

Wockhardt has allotted 8,610 equity shares under ESOS in 26 August 2024. With this allotment, the paid-up equity share capital of the Company will increase from Rs.76,70,04,680/- (15,34,00,936 equity shares of Rs.5/- each) to Rs. 76,70,47,730/- (15,34,09,546 equity shares of Rs.5/- each).Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Wockhardt reports consolidated net loss of Rs 14.00 crore in the June 2024 quarter

Net Loss of Wockhardt reported to Rs 14.00 crore in the quarter ended June 2024 as against net loss of Rs 134.00 crore during the previous quarter ended June 2023. Sales rose 14.75% to Rs 739.00 crore in the quarter ended June 2024 as against Rs 644.00 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales739.00644.00 15 OPM %12.312.48 - PBDT48.00-49.00 LP PBT-6.00-104.00 94 NP-14.00-134.00 90 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Wockhardt to table results

Wockhardt will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live